Gene · 3978
Papers1,551
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,551
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dynamic view of an allosteric intermediate in a positively cooperative dimer. | bioRxiv | 2026 | 42798384 | PubTator, text mining | PubMed |
| Identification of Potential SARS-CoV-2 Main Protease (MPro) Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Approaches. | Int J Mol Sci | 2026 | 42737581 | PubTator, text mining | PubMed |
| Comprehensive In Silico Analysis Identifies MSTO1 and LIG1 as Candidate Biomarkers With Diagnostic and Prognostic Relevance in Hepatocellular Carcinoma. | Cancer Rep (Hoboken) | 2026 | 42732946 | PubTator, text mining | PubMed |
| Integrated expression profiling of BCR-ABL and computational identification of ABL1 inhibitors in pediatric acute lymphoblastic leukemia. | In Silico Pharmacol | 2026 | 42707602 | PubTator, text mining | PubMed |
| Revealing the Association of LIG1 Genetic Variants With Pterygium Susceptibility and Demographic Characteristics in a Taiwanese Population. | In Vivo | 2026 | 42665426 | PubTator, text mining | PubMed |
| Cyclosporine Stabilized the Hemoglobin Level in Children With Novel Compound Heterozygous Mutations in the LIG1 Gene: A Single Case Report. | Pediatr Blood Cancer | 2026 | 42527943 | PubTator, text mining | PubMed |
| LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations. | Mol Cancer Ther | 2026 | 42456172 | PubTator, text mining | PubMed |
| Targeting LIG1 to overcome oxaliplatin resistance by inducing PANoptosis in colorectal cancer. | Drug Resist Updat | 2026 | 42442130 | PubTator, text mining | PubMed |
| Tissue-specific CTG•CAG expansion rate and disease severity are modified by DNA repair genes expression levels in myotonic dystrophy type 1 patients. | DNA Repair (Amst) | 2026 | 42419013 | PubTator, text mining | PubMed |
| RNA helicase DDX5 alleviates UVB-induced skin DNA damage through RBM15/METTL14-mediated m6A modification. | J Photochem Photobiol B | 2026 | 42296715 | PubTator, text mining | PubMed |
| Arginine deprivation enhances ASS1-negative glioblastoma radiosensitivity via epigenetic silencing of DNA repair genes. | Cell Death Dis | 2026 | 42218164 | PubTator, text mining | PubMed |
| XPF mediates 3' flap processing for FEN1-independent Okazaki fragment maturation. | Nucleic Acids Res | 2026 | 42186816 | PubTator, text mining | PubMed |
| A sibling study of variation in parental mutation rates. | bioRxiv | 2026 | 42182135 | PubTator, text mining | PubMed |
| PARP1-mediated 5' flap dynamics facilitate Okazaki fragment maturation. | bioRxiv | 2026 | 42094445 | PubTator, text mining | PubMed |
| Mechanistic Investigation of the DNA Ligase I Deficiency Variant A624T. | Biochemistry | 2026 | 42047708 | PubTator, text mining | PubMed |
| E2F Accelerates the Proliferation of B-Cell Non-Hodgkin Lymphomas by Upregulating Cell-Cycle Genes. | Curr Med Sci | 2026 | 42043646 | PubTator, text mining | PubMed |
| Stress granules promote DNA damage repair through the G3BP1/NAT10/ATF3 axis to facilitate nasopharyngeal carcinoma progression. | Oncogene | 2026 | 42032366 | PubTator, text mining | PubMed |
| Comprehensive Multi-Omics Characterization of CYP2R1 as a Diagnostic and Functional Biomarker in Hepatocellular Carcinoma. | Med Sci (Basel) | 2026 | 42029602 | PubTator, text mining | PubMed |
| Genetic Markers of Tumor Multiplicity in Non-melanoma Skin Cancer: Associations of 19 SNPs in an Italian Cohort. | Dermatol Ther (Heidelb) | 2026 | 41964798 | PubTator, text mining | PubMed |
| Fidelity of DNA ligase I is sensitive to physiological Mg2+ level. | J Biol Chem | 2026 | 41895445 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3978/papers